MYDX.files patents.with an “s” not patent:
Post# of 1481
(Total Views: 401)
Posted On: 12/01/2017 12:17:09 AM
MYDX.files patents.with an “s” not patent:
https://ir.mydxlife.com/press-releases/detail...rs-for-the
“...Bluetooth technology capable of monitoring dosages and consumer feedback.”
Is there any other electronic vaping device period with technology that allows for dosage monitoring? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic vaping device. Any other medicinal electronic vaping device with technology that allows for monitoring doses? There’s a patent. Add a patent for offering consumer feedback technology directly relating to a medicinal electronic vaping device. Any other electronic cannabis vaping device with technology that allows for dosage monitoring? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic cannabis vaping device. Any other electronic medicinal cannabis vaping device with technology that allows for monitoring doses? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic medicinal cannabis vaping device.
Any company wanting to monetize a product requiring any of MYDX’s patent-pending product technologies will have to go through MYDX. They might as well just go directly to MYDX 360 and look into “Powered By MYDX” product offerings.
“A Game-Changing Innovation That Helps to Raise the Standard of Safety in Cannabis”
Why is this important? Because the only chance cannabis has in changing legislation is proof of responsibility at the very least in the medicinal arena and is the only way to begin the process to be recognized for medical insurance purposes. For any responsible consumer who chooses products that reflect responsibility, where are those consumers to go? MYDX is the only answer for responsible consumers. MYDX is not the company offering products for consumers who believe that keeping their cannabis away from kids is responsibly safe. Is a stash in a zipped bag in the back of a drawer the kind of responsible consumer MYDX is seeking? Seeking to reform, yes and seeking those responsible enough to say a zipped bag in the back of a drawer is not good enough. MYDX is the answer for consumers seeking the most safe product available in the market. Safety goes beyond accountability in dosage monitoring and directly to the ECOSmartPens functionality with lock/unlock feature via Bluetooth device for electronic medicinal vaping with/without cannabis content. That’s a patent.
“ECOSmartPen App”, I would expect a PR soon regarding availability of new APP.
Further down the PR, it states this:
“MyDx's patents cover the delivery pen's child-safety locks, dosage control and tracking and related technologies unique to the next-generation delivery pen that monitors how many doses or "puffs" it takes for strains/formulas to take effect per individual – personalized medicine.”
All this is reflective of the above patent potential.
“Approaching 3,000 testers in circulation, MyDx has built, and continues to build upon, a comprehensive database of user and consumption information that is now being used to drive policy; educate and inform industry stakeholders such as doctors, consumers, entrepreneurs, and politicians; and, promote a higher level of public safety and concern.
MyDx is the only company in the world that actively tracks and analyzes (in real time) how strains impact consumers and alleviate ailments. While this is important to the legitimacy of the industry, given the current lack of oversight, it's also a public safety concern.”
All this is reflective of how great a position MYDX is in when the company’s data will be accessed by all sorts of special interest entrepreneurs for new product development. All this equates to money for MYDX. What many fail to recognize and what the competition keeps ignoring/wishes not to happen is the legitimacy cannabis has on humans as a medicine to cure ailments and many fail to recognize and those who recognize such as the competition wish not to recognize that MYDX will be the only company with significant data offering answers to questions that will help stimulate policy as this indicates:
"Today, doctors only offer prescriptions for medicinal marijuana, generally. They don't provide any recommendations on what to use and when and how to use it. And that's a public safety problem. We know from our data that not all cannabis is the same (not even the names), which is why our customers use our handheld testers. But the one piece of data we didn't have was knowing how much of a certain chemical profile it took to achieve its desired effect. Hence the creation of the ECO Smart Pen," said Daniel Yazbeck, CEO of MyDx. "We will not only offer patients a way to Trust & Verify® their products, but, with the ECO Smart Pen, they will be able to determine for themselves how much they need to consume to achieve their desired effect. In combination with MyDx360, doctors and administrators will also be able to better monitor their patient's habits and offer more targeted prescriptions."
This last part is my favorite from the article:
“With the addition of the ECO Smart Pen to the MyDx Ecosystem, MyDx will capture and house the most comprehensive dataset of marijuana consumption in the world. This new data will then inform the company's foray into identifying green active biopharmaceuticals (gAPI).”
Who would not want to invest in the company offering most datasets generated by the consumers purchasing and using said company’s product currently and with the addition of the patent-pending vape pen to accumulate significant data is only strengthening its already dominating position.
I want to invest in the company generating and offering the most monetized data from human cannabis consumption building the future for medicinal cannabis. Is there any company currently capable of this that is not MYDX?
This is exactly why I am and always will be a MYDX shareholder investor accumulating as many shares under .25 as possible before MYDX possibly uplists to NASDAQ in 2020.
With the data cross-referencing potential with Phylos Bioscience, MYDX will be an unbeatable force of significant data correlating individual ailment relief to a specific cannabis genome.
The only reason I’m able to afford a couple million shares in a company with this potential is the great expense of the technology required before it is met with big money investors. It won’t be long I believe until MYDX is trading at .25 and there is no way I could ever afford a couple million shares at that price, especially not in the amount of time before it goes multi dollar.
https://ir.mydxlife.com/press-releases/detail...rs-for-the
“...Bluetooth technology capable of monitoring dosages and consumer feedback.”
Is there any other electronic vaping device period with technology that allows for dosage monitoring? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic vaping device. Any other medicinal electronic vaping device with technology that allows for monitoring doses? There’s a patent. Add a patent for offering consumer feedback technology directly relating to a medicinal electronic vaping device. Any other electronic cannabis vaping device with technology that allows for dosage monitoring? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic cannabis vaping device. Any other electronic medicinal cannabis vaping device with technology that allows for monitoring doses? There’s a patent. Add a patent for offering consumer feedback technology directly relating to an electronic medicinal cannabis vaping device.
Any company wanting to monetize a product requiring any of MYDX’s patent-pending product technologies will have to go through MYDX. They might as well just go directly to MYDX 360 and look into “Powered By MYDX” product offerings.
“A Game-Changing Innovation That Helps to Raise the Standard of Safety in Cannabis”
Why is this important? Because the only chance cannabis has in changing legislation is proof of responsibility at the very least in the medicinal arena and is the only way to begin the process to be recognized for medical insurance purposes. For any responsible consumer who chooses products that reflect responsibility, where are those consumers to go? MYDX is the only answer for responsible consumers. MYDX is not the company offering products for consumers who believe that keeping their cannabis away from kids is responsibly safe. Is a stash in a zipped bag in the back of a drawer the kind of responsible consumer MYDX is seeking? Seeking to reform, yes and seeking those responsible enough to say a zipped bag in the back of a drawer is not good enough. MYDX is the answer for consumers seeking the most safe product available in the market. Safety goes beyond accountability in dosage monitoring and directly to the ECOSmartPens functionality with lock/unlock feature via Bluetooth device for electronic medicinal vaping with/without cannabis content. That’s a patent.
“ECOSmartPen App”, I would expect a PR soon regarding availability of new APP.
Further down the PR, it states this:
“MyDx's patents cover the delivery pen's child-safety locks, dosage control and tracking and related technologies unique to the next-generation delivery pen that monitors how many doses or "puffs" it takes for strains/formulas to take effect per individual – personalized medicine.”
All this is reflective of the above patent potential.
“Approaching 3,000 testers in circulation, MyDx has built, and continues to build upon, a comprehensive database of user and consumption information that is now being used to drive policy; educate and inform industry stakeholders such as doctors, consumers, entrepreneurs, and politicians; and, promote a higher level of public safety and concern.
MyDx is the only company in the world that actively tracks and analyzes (in real time) how strains impact consumers and alleviate ailments. While this is important to the legitimacy of the industry, given the current lack of oversight, it's also a public safety concern.”
All this is reflective of how great a position MYDX is in when the company’s data will be accessed by all sorts of special interest entrepreneurs for new product development. All this equates to money for MYDX. What many fail to recognize and what the competition keeps ignoring/wishes not to happen is the legitimacy cannabis has on humans as a medicine to cure ailments and many fail to recognize and those who recognize such as the competition wish not to recognize that MYDX will be the only company with significant data offering answers to questions that will help stimulate policy as this indicates:
"Today, doctors only offer prescriptions for medicinal marijuana, generally. They don't provide any recommendations on what to use and when and how to use it. And that's a public safety problem. We know from our data that not all cannabis is the same (not even the names), which is why our customers use our handheld testers. But the one piece of data we didn't have was knowing how much of a certain chemical profile it took to achieve its desired effect. Hence the creation of the ECO Smart Pen," said Daniel Yazbeck, CEO of MyDx. "We will not only offer patients a way to Trust & Verify® their products, but, with the ECO Smart Pen, they will be able to determine for themselves how much they need to consume to achieve their desired effect. In combination with MyDx360, doctors and administrators will also be able to better monitor their patient's habits and offer more targeted prescriptions."
This last part is my favorite from the article:
“With the addition of the ECO Smart Pen to the MyDx Ecosystem, MyDx will capture and house the most comprehensive dataset of marijuana consumption in the world. This new data will then inform the company's foray into identifying green active biopharmaceuticals (gAPI).”
Who would not want to invest in the company offering most datasets generated by the consumers purchasing and using said company’s product currently and with the addition of the patent-pending vape pen to accumulate significant data is only strengthening its already dominating position.
I want to invest in the company generating and offering the most monetized data from human cannabis consumption building the future for medicinal cannabis. Is there any company currently capable of this that is not MYDX?
This is exactly why I am and always will be a MYDX shareholder investor accumulating as many shares under .25 as possible before MYDX possibly uplists to NASDAQ in 2020.
With the data cross-referencing potential with Phylos Bioscience, MYDX will be an unbeatable force of significant data correlating individual ailment relief to a specific cannabis genome.
The only reason I’m able to afford a couple million shares in a company with this potential is the great expense of the technology required before it is met with big money investors. It won’t be long I believe until MYDX is trading at .25 and there is no way I could ever afford a couple million shares at that price, especially not in the amount of time before it goes multi dollar.
(0)
(0)MyDx, Inc. (MYDX) Stock Research Links
Scroll down for more posts ▼